Results 201 to 210 of about 52,085,429 (356)

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Bayesian Sample Size Calculations for External Validation Studies of Risk Prediction Models. [PDF]

Stat Med
Sadatsafavi M, Gustafson P, Setayeshgar S, Wynants L, D Riley R.   +4 more
europepmc   +1 more source

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

Molecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis, Jack V. Mills, Wojciech Niedzwiedz, Valentine M. Macaulay   +3 more
wiley   +1 more source

Laser doppler holography for choroidal blood flow assessment: a systematic review of technical capabilities, validation studies, and clinical applications. [PDF]

Front Ophthalmol (Lausanne)
Marco Giammanco M, Russo GGB, Giammanco M.   +2 more
europepmc   +1 more source

Portuguese version of the CDR plus NACC FTLD: Validation studies. [PDF]

Alzheimers Dement (Amst), 2022
Lima M, Tábuas-Pereira M, Durães J, Faustino P, Simões MR, Kukull W, Knopman DS, Santana I.   +7 more
europepmc   +1 more source

Flow Enabled Target Capture Halbach‐based magnetic enrichment increases circulating tumor cell capture from blood in metastatic cancer patients

Molecular Oncology, EarlyView.
Pair‐wise comparison of the CellSearch and FETCH enrichment technologies for circulating tumor cells (CTCs) from metastatic breast, prostate, and small cell lung cancer patients shows an increased capture of CTCs using FETCH enrichment. The clinical implementation of circulating tumor cells (CTCs) as a predictive tool for therapy efficacy in the ...
Michiel Stevens, Anouk Mentink, Tom Niessink, Frank Coumans, Leonie Mekenkamp, Ruchi Bansal, Jeroen Hiltermann   +6 more
wiley   +1 more source

Evaluación psicométrica y desarrollo de una versión reducida de la nueva escala de ansiedad en una muestra hospitalaria de Lima, Perú

Revista Peruana de Medicina Experimental y Salud Pública
Objetivos. Evaluar las propiedades psicométricas y desarrollar una versión reducida de la nueva escala de ansiedad. Materiales y métodos. La nueva escala de ansiedad de 130 ítems (NEA-130) se aplicó a 254 pacientes psiquiátricos ambulatorios de un ...
Antonio Lozano-Vargas, Johann Vega-Dienstmaier   +1 more
doaj  

Comprehensive quantum chemical analysis, vibrational spectroscopy, molecular docking, ADMET, and in vitro validation studies of hydroxychloroquine-MRGPRX2 complex in IDH-wildtype glioblastoma. [PDF]

PLoS One
Demirag AD, Aksoy RA, Akman G, Kaya V, Yildirim M.   +4 more
europepmc   +1 more source

Systematic Review of Fitbit Charge 2 Validation Studies for Exercise Tracking. [PDF]

Transl J Am Coll Sports Med, 2022
Irwin C, Gary R.
europepmc   +1 more source

USP29‐regulated noncanonical stabilization of the hypoxia‐inducible factor‐α in aggressive prostate cancer

Molecular Oncology, EarlyView.
We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober, Leire Moreno‐Cugnon, Laura Martínez‐Pérez, Amaia Ercilla, Amaia Zabala‐Letona, Adrián Vicente‐Barrueco, Maider Fagoaga‐Eugui, Saioa Garcia‐Longarte, Blanca Calle‐Ciborro, Encarnación Pérez‐Andrés, Onintza Carlevaris, Sara Pozo, Isabel Mendizabal, Ugo Mayor, Arkaitz Carracedo, Violaine Sée, Edurne Berra   +16 more
wiley   +1 more source